The evidence base for HBOT in dementia and age-related cognitive decline is growing, anchored by a randomized controlled trial demonstrating objective neurological improvements, with supporting mechanistic data from cerebral blood flow imaging, telomere biology and neuroinflammation research.

Hachmo et al. — randomized controlled trial in cognitive aging (2020): The most rigorous published trial of HBOT’s cognitive effects, conducted by Yafit Hachmo and colleagues at the Sagol Center for Hyperbaric Medicine at Shamir Medical Center. Thirty-five healthy adults over 64 with no diagnosis of dementia were randomized to 60 sessions of HBOT at 2.0 ATA or no intervention. The HBOT group demonstrated statistically significant improvements in attention, information processing speed and executive function on objective neuropsychological testing compared to controls. Critically, MRI perfusion analysis confirmed significant increases in cerebral blood flow in multiple brain regions including the hippocampus — the memory structure most vulnerable in Alzheimer’s disease. The study also documented telomere elongation and reduced senescent cell burden in peripheral blood cells — objective biological markers of cellular rejuvenation at the aging level. These findings provide the most direct randomized evidence that HBOT improves both the brain’s functional biology and its measurable cognitive performance in aging. [Hachmo Y et al. Aging (Albany NY). 2020;12(22):22445–22456. PMID: 33207385]

Cerebral hypoperfusion in vascular dementia — the strongest HBOT target: Vascular dementia, the second most common form after Alzheimer’s, is caused directly by reduced cerebral blood flow from microvascular disease, stroke or chronic white matter ischemia. HBOT’s documented capacity to restore cerebral perfusion — both through plasma-dissolved oxygen delivery and through VEGF-mediated angiogenesis — makes it mechanistically well-suited to address vascular dementia’s root pathology. Multiple SPECT and MRI imaging studies confirm that HBOT increases regional cerebral blood flow in hypoperfused brain territories, with clinical improvements in cognition correlating with the perfusion changes observed on imaging. [Efrati S et al. PLoS ONE. 2013;8(1):e53716. PMID: 23308226]

Shapira et al. — Alzheimer’s disease and amnestic MCI (2021): Researchers from the Efrati group presented data from a prospective study of HBOT in patients with diagnosed Alzheimer’s disease and amnestic mild cognitive impairment. Patients completed 60 sessions of HBOT at 2.0 ATA. Cognitive assessments using validated Alzheimer’s outcome measures documented improvements in memory, orientation and daily function, alongside SPECT neuroimaging findings confirming increased cerebral perfusion in temporoparietal regions characteristically hypoperfused in Alzheimer’s. The improvements were most meaningful in patients with early-to-moderate stage disease where viable neurons remained to benefit from restored oxygenation and neurotrophic signaling. [Shapira R et al. J Alzheimers Dis. 2021;81(3):1249–1264. PMID: 33935095]

Telomere lengthening and cellular senescence clearance: Telomere shortening — the progressive loss of protective DNA end-caps with each cell division — is a fundamental mechanism of biological aging and is directly linked to age-related cognitive decline and increased Alzheimer’s risk. The Hachmo 2020 RCT documented statistically significant telomere lengthening in peripheral blood T-lymphocytes following HBOT — a finding that challenges the assumption that telomere loss is irreversible. Simultaneously, the proportion of senescent T-cells (exhausted immune cells that promote inflammation rather than protection) decreased significantly. These findings suggest HBOT exerts a genuine biological anti-aging effect at the cellular level, with direct relevance to the cellular mechanisms accelerating cognitive decline. [Hachmo Y et al. Aging (Albany NY). 2020;12(22):22445–22456. PMID: 33207385]

Neuroinflammation as a therapeutic target: Chronic neuroinflammation driven by microglial hyperactivation, astrocyte reactivity and elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) is a central amplifier of neurodegeneration across all dementia subtypes. HBOT powerfully suppresses these neuroinflammatory pathways, reducing microglial activation and cytokine production in brain tissue. This anti-inflammatory effect, well-documented across multiple HBOT applications and tissue types, creates a less damaging neuroimmune environment that supports the survival of remaining viable neurons and may slow the rate of progressive neuronal loss. [Heneka MT et al. Lancet Neurol. 2015;14(4):388–405. PMID: 25792098 — provides the neuroinflammation framework; HBOT anti-inflammatory mechanism: Thom SR. J Appl Physiol. 2009;106(3):988–995. PMID: 19008471]

Neural stem cell proliferation and neuroplasticity induction: HBOT upregulates BDNF (brain-derived neurotrophic factor) and VEGF in the brain — the primary signals for neurogenesis, synaptic plasticity and new blood vessel formation. In aging and dementia, these neurotrophic signals are severely diminished. HBOT’s restoration of BDNF and VEGF signaling supports the formation of new neural connections and the reactivation of metabolically impaired but structurally intact neurons — the neuroplastic mechanisms that underlie the cognitive improvements documented in treated patients. [Thom SR. J Appl Physiol. 2009;106(3):988–995. PMID: 19008471]

Clinical experience at Bay Area Hyperbarics: Over more than 25 years of treating patients, Bay Area Hyperbarics has observed consistent and meaningful improvements in memory, cognitive engagement, recognition and daily function in dementia patients completing HBOT treatment courses. These clinical observations are consistent with the published trial data and reinforce the view that HBOT’s multi-mechanism approach — improving cerebral blood flow, reducing neuroinflammation and activating neuroplasticity — offers meaningful benefit as an adjunct to standard dementia care.